ADMA

Insider Trades

Name	Value	Action	Price	Current Price
Grossman Jerrold BDirector $51k6.4k shares BuyMay 27, 2026 $7.91 --
Grossman Jerrold BDirector $100k12.5k shares BuyMay 12, 2026 $8.01 --
Grossman Jerrold BDirector $100k12.5k shares BuyMay 11, 2026 $8.01 --
Grossman Adam SDirector, Officer: President And CEO $227k15k shares SellMar 16, 2026 $15.16 --
Grossman Adam SDirector, Officer: President And CEO $91k6k shares SellMar 16, 2026 $15.16 --
Kestenberg-Messina Kaitlin M.COO And SVP, Compliance $158k10.1k shares SellMar 9, 2026 $15.63 --

News

gurufocus.comADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadlinegurufocus.comJun 19

prnewswire.comADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadlineprnewswire.comJun 19

newsfilecorp.comADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadlinenewsfilecorp.comJun 19

globenewswire.comADMA INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuitglobenewswire.comJun 19

globenewswire.comROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMAglobenewswire.comJun 19

Trade ADMA

About ADMA Biologics, Inc.

ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.

CEO: Adam S. Grossman
IPO Date: Oct 17, 2013

Market Data

Open: $8.52
High: $8.62
Low: $8.29
Volume: 6.8M
Avg Volume: 7.1M
52W High: $20.46
52W Low: $7.21

Valuation

Market Cap: $1.9B
Enterprise Value: $2.0B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $28M
Revenue: $510M
Net Income: $147M
Cash: $88M
Debt: $80M

Events

EarningsAug 5

EPS est. 0.16